<DOC>
	<DOC>NCT00763503</DOC>
	<brief_summary>This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3Âµg/g oily spray twice daily (6 g daily), applied to 20% of BSA for 3 weeks. There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and Treatment period (Day 1/ Baseline, Day 15 and Day 22).</brief_summary>
	<brief_title>Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Diagnosis of plaquetype psoriasis involving 10% 20% of body surface area (BSA), with a Global Severity Score of at least 3 (moderate) Other type of psoriasis (other than plaque) Significant abnormal lab findings Secondary hyperparathyroidism Vit D deficiency Hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>PK</keyword>
	<keyword>calcitriol</keyword>
</DOC>